Table 3. Characteristics of patients with brain metastases (BMs) who did and did not receive upfront local treatment for brain lesions.
| Characteristic | Patients with BMs with upfront local treatment | Patients with BMs without upfront local treatment | P-value |
|---|---|---|---|
| (n = 39) | (n = 43) | ||
| Sex, n (%) | 0.567 | ||
| M | 16 (41.0) | 15 (34.9) | |
| F | 23 (59.0) | 28 (65.1) | |
| Smoking status, n (%) | 0.521 | ||
| Never smoked | 27 (69.2) | 34 (79.1) | |
| Ex-smokera | 4 (10.3) | 4 (9.3) | |
| Current smoker | 8 (20.5) | 5 (11.6) | |
| ECOG PS, n (%) | < 0.001* | ||
| 0 | 5 (12.8) | 16 (37.1) | |
| 1 | 21 (53.8) | 25 (58.1) | |
| 2–4 | 13 (33.4) | 2 (4.7) | |
| Presence of neurological symptoms, n (%) | 23 (59.0) | 5 (11.6) | < 0.001* |
| Patterns of BMs, n (%) | |||
| Single metastasis | 14 (35.9) | 8 (18.6) | 0.078 |
| The largest tumor > 3cm in diameter | 12 (30.8) | 0 | < 0.001* |
| Intracranial hemorrhage | 4 (10.3) | 0 | <0.001* |
| Leptomeningeal carcinomatosis | 1 (2.6) | 5 (11.6) | 0.115 |
| EGFR mutation status, n (%) | 0.361 | ||
| Group 1c | 29 (74.4) | 36 (83.7) | |
| Group 2d | 1 (2.6) | 2 (4.7) | |
| Group 3e | 9 (23.1) | 5 (11.6) |
*P < 0.05.
aCeased smoking >1 year before diagnosis.
bSignificant weight loss of >10.0% within 6 months of diagnosis.
cClassical mutation(s).
dComplex mutation with classical mutation.
eRare mutation with or without complex mutation.
BM, brain metastases; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; F, female; M, male; PD, progressive disease; PS, performance status.